August Featured Clinical Trials

KALO 1Z12

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Disease: Leukemia

Objective: The primary objective is to determine a possible maximum tolerated dose (MTD, defined in Section 7.1.1) for KB004 when administered up to 700 mg once weekly by IV infusion to subjects with hematologic malignancies.

MEI 1914

Disease: Myelodysplastic Syndrome (MDS)

Advertising Policy

Objective: The primary objective is to Estimate Clinical Improvement rate including Complete Responses (CR), Marrow CR, Partial Responses (PR), Hematologic Improvement (HI) (CR+Marrow CR+PR+HI).

 MEI 1913

Disease: Myelodysplastic Syndrome (MDS)

Objective: The primary objective is to estimate the relative efficacy, as measured by CR at or before the Cycle 6 response assessment following randomization of pracinostat plus azacitidine versus placebo plus azacitidine.

Advertising Policy

GENE 1513

Disease: Lung

Objective: The primary objective is to evaluate the efficacy of MPDL3280A in patients with PD-L1- positive locally advanced or metastatic NSCLC.

Photo by Russell Lee